HC Wainwright & Co. Maintains Buy Rating for Cytokinetics: Here's What You Need To Know
Portfolio Pulse from Benzinga Insights
HC Wainwright & Co. has maintained its Buy rating for Cytokinetics (NASDAQ:CYTK) and raised its price target from $49.00 to $58.00. This new target price represents a 73.24% increase from the current share price. Cytokinetics is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue.
October 20, 2023 | 5:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has maintained its Buy rating for Cytokinetics and raised its price target, indicating a positive outlook for the company's stock.
The decision by HC Wainwright & Co. to maintain a Buy rating and raise the price target for Cytokinetics indicates a positive outlook for the company's stock. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100